TapewireFind a company

person · Reporting owner

Dethlefs Sven

Disclosed activity across 1 company

Tapewire entity
115808
SEC CIK
0001726010

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063EVP, North America CommercialMarch 06, 2023March 08, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date March 06, 2023 · Filed March 08, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect165,381 Last balance in matching sequence After 2023-03-07 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2023-03-06 · Sale · Disposed 19,355 · Balance 223,447

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Row 2 · 2023-03-07 · Sale · Disposed 58,066 · Balance 165,381

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 07, 2023 Filed Mar 8, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 58,066 $9.43 $547,440.44
Disclosure

SEC source: 0001209191-23-017155 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,381

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 06, 2023 Filed Mar 8, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 19,355 $9.93 $192,212.57
Disclosure

SEC source: 0001209191-23-017155 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,447

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 24,952 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016688 · doc4.xml · derivative · entry 7

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,905

Underlying: Ordinary Shares · 24,952 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 24,952 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025.

F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 24,952 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 24,952 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016688 · doc4.xml · nonDerivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 38,538 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016688 · doc4.xml · derivative · entry 6

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,617

Underlying: Ordinary Shares · 38,538 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,538 vested on March 4, 2023, 33,538 vesting on each of March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,538 vested on March 4, 2023, 33,538 vesting on each of March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 13,931 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016688 · doc4.xml · derivative · entry 5

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 13,931 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 vested on each of March 4, 2021 and March 4, 2022, and 13,931 vested on March 4, 2023.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 vested on each of March 4, 2021 and March 4, 2022, and 13,931 vested on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 38,538 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016688 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 13,931 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016688 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,312

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 99,601 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016688 · doc4.xml · derivative · entry 4

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,601

Underlying: Ordinary Shares · 99,601 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 42,309 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-014436 · doc4.xml · derivative · entry 6

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 42,309 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.

F6 · derivative.expiration_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 17,346 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-014436 · doc4.xml · derivative · entry 5

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,346

Underlying: Ordinary Shares · 17,346 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 17,346 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 17,346 vesting on February 28, 2024.

F5 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 17,346 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 17,346 vesting on February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 42,309 $9.89 $418,292.16
Disclosure

SEC source: 0001209191-23-014436 · doc4.xml · nonDerivative · entry 4

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,381

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 42,309 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-014436 · doc4.xml · nonDerivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,690

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 17,346 $9.89 $171,492.96
Disclosure

SEC source: 0001209191-23-014436 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,381

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 17,346 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-014436 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 12:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 42,309 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-007950 · doc4.xml · derivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,309

Underlying: Ordinary Shares · 42,309 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 6,993 $7.37 $51,515.33
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 5

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,381

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 24,952 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · derivative · entry 9

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,857

Underlying: Ordinary Shares · 24,952 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F10 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 24,952 having vested on March 5, 2022, 24,952 vesting on each of March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025.

F10 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 24,952 having vested on March 5, 2022, 24,952 vesting on each of March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 24,952 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 4

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 154,155 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · derivative · entry 8

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,155

Underlying: Ordinary Shares · 154,155 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 38,538 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026.

F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 38,538 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 13,930 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · derivative · entry 7

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,931

Underlying: Ordinary Shares · 13,930 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023.

F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 37,939 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · derivative · entry 6

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 37,939 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.

F7 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 3,904 $7.48 $29,211.68
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,422

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 13,930 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,326

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 37,939 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,396

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:43 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 17,346 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-014467 · doc4.xml · derivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,692

Underlying: Ordinary Shares · 17,346 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 17,346 having vested on each of February 28, 2021 and February 28, 2022, and 17,346 vesting on each of February 28, 2023 and February 28, 2024.

F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 17,346 having vested on each of February 28, 2021 and February 28, 2022, and 17,346 vesting on each of February 28, 2023 and February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:43 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 4,862 $8.14 $39,587.38
Disclosure

SEC source: 0001209191-22-014467 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,457

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:43 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 17,346 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-014467 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,319

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 13,135 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-008412 · doc4.xml · derivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 13,135 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 4,138 $9.06 $37,491.11
Disclosure

SEC source: 0001209191-22-008412 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,973

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 13,135 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-008412 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,111

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 08, 2022 Filed Feb 10, 2022 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 37,939 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-008412 · doc4.xml · derivative · entry 4

Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,939

Underlying: Ordinary Shares · 37,939 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.

F7 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 99,809 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-018510 · doc4.xml · derivative · entry 4

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,809

Underlying: Ordinary Shares · 99,809 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 24,952 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 24,953 vesting on March 5, 2025.

F7 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 24,952 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 24,953 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 13,930 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-018510 · doc4.xml · derivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,861

Underlying: Ordinary Shares · 13,930 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023.

F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 6,012 $10.57 $63,523.39
Disclosure

SEC source: 0001209191-21-018510 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,975.7

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.690, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 13,930 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-018510 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,987.7

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2021 Filed Mar 4, 2021 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,400 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-017756 · doc4.xml · derivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2021 Filed Mar 4, 2021 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 606 $10.86 $6,582.74
Disclosure

SEC source: 0001209191-21-017756 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,057.7

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.835 to $10.910, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2021 Filed Mar 4, 2021 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 1,400 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-017756 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,663.7

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 7,486 $10.83 $81,079.37
Disclosure

SEC source: 0001209191-21-015826 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,263.7

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2021 Filed Mar 2, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 17,346 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-015826 · doc4.xml · derivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,038

Underlying: Ordinary Shares · 17,346 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 17,346 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024.

F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 17,346 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2021 Filed Mar 2, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 17,346 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-015826 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,749.7

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 13,135 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-009628 · doc4.xml · derivative · entry 5

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,135

Underlying: Ordinary Shares · 13,135 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F8 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F8 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 23,962 $12.69 $304,185.61
Disclosure

SEC source: 0001209191-21-009628 · doc4.xml · nonDerivative · entry 4

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,403.7

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 5,695 $12.69 $72,295.18
Disclosure

SEC source: 0001209191-21-009628 · doc4.xml · nonDerivative · entry 3

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,365.7

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantOrdinary Shares 55,287 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-009628 · doc4.xml · nonDerivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,060.7

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units.

F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 13,135 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-009628 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,773.7

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:32 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,179 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-020162 · doc4.xml · derivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,179 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020.

F3 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:32 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 1,179 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-020162 · doc4.xml · nonDerivative · entry 1

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,638.7

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2020 Filed Mar 5, 2020 13:10 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,399 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-016459 · doc4.xml · derivative · entry 2

Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Ordinary Shares · 1,399 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.